Search results
Results from the WOW.Com Content Network
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
CRSP Market Cap data by YCharts. 3. Intensive competition. The success of CRISPR Therapeutics will depend on its ability to bring multiple new drugs to the market to support a more viable business ...
The last reason to buy this stock today is that its balance sheet is looking as good as it gets in biotech. At the end of the first quarter, it had around $2.1 billion in cash, cash equivalents ...
CRISPR Therapeutics (NASDAQ: CRSP), ... Its price in the U.S. is $2.2 million. Its total addressable market includes about 35,000 patients in the U.S. and Europe and an additional 23,000 in Saudi ...
The gene-editing therapy specialist is rising in prominence. For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day. CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should ...
For premium support please call: 800-290-4726 more ways to reach us